3 NZX penny stocks turning heads today despite a weak market

3 min read | January 25, 2022 09:07 PM NZDT | By Sonal

Highlights

  • New Zealand's small-caps subindex also traded in red for the day with the S&P/NZX SmallCap index posting a drop of 0.5%.
  • Rakon, Chatham Rock and Green Cross are creating a buzz today.
  • Investors must exercise caution while picking penny stocks.

NZ’s benchmark index, the S&P/ NZX 50, ended the trading session in red today at 12,128.21, down 0.52% from its previous close.

The local small-caps subindex also traded in red for the day with the S&P/NZX SmallCap index posting a drop of 0.5% on the day at 93,023.76. However, some stocks are staying unimpacted by a weak market and are registering gains.

We have compiled a list of 3 NZX penny stocks trading under $5 that reported substantial gains during the day.

3 NZX Penny Stocks

Image source: © 2021 Kalkine Media®, Data source- EODHD/Others

Rakon Limited (NZX:RAK)

A global leader in frequency control and timing solutions, Rakon, announced on Tuesday that it had hired Sinead Horgan as its independent Non-Executive Director.

Ms Hogan has extensive financial, risk management as well as M&A experience at the board and executive level. She has been chosen as an additional director as per the Company’s ongoing Board succession programme. ­­

ALSO READ: How will these 4 retail stocks fare amid new Omicron wave?

Previously, Rakon’s Chairman Bruce Irvine had intended to retire from the Board once the planning succession programme was completed.

On 25 January, BNZ ended the trading session at $1.8, up 11.11% from its previous close.

Chatham Rock Phosphate Limited (NZX:CRP) 

Phosphate exploration and development company Chatham Rock announced this month that it would undertake the planned manufacturing of Dicalcium Phosphate (DCP) at Korella South. The prefeasibility study for the production has begun.

Internal talks related to DCP production had begun in January 2021. An elaborate study for the positioning of the DCP plant was started with Prayon SA in relation to supplying 3 key elements.

DO READ: Which are 5 NZX dividend stocks to explore in 2022?

On 25 January, CRP ended the trading session at $0.139, up 6.11% from its previous close.

Green Cross Health Limited (NZX:GXH)

Primary healthcare provider Green Cross Health provided its trading update on Tuesday. The Group notified that it was witnessing higher-than-expected revenue and profitability. GXH saw an increase in revenue of nearly 14% for the 9 months ended 31 December 2021 due to increased activity related to the COVID-19 pandemic in the Company’s divisions and recent acquisitions in the medical division.

ALSO READ: Why to look at 3 prominent NZ insurers?

GXH CEO Rachael Newfield stated that the rise might not continue in the next financial year due to an ambiguous and unpredictable view for COVID-19 vaccination and wiping activity.

NPAT for the 12 months to 31 March 2022 is likely to exceed the previous period result by $4.5 million to $6.5 million.

On 25 January, GXH ended the trading session at $1.18, up 2.61% from its previous close.

Bottom Line

Investors may get attracted to investing in penny stocks due to their potential of providing high returns. However, they can prove to be highly risky and erode investors’ wealth in the blink of an eye. Hence, investors must exercise caution while investing in penny stocks.

(NOTE: Currency is reported in NZ Dollar unless stated otherwise)


Disclaimer

The content on this website, including, but not limited to, any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (“Content”) is a service provided by Kalkine Media New Zealand Limited (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide financial advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests users seek financial advice from a financial advice provider, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all liability to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without any express or implied warranties of any kind. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit a source wherever it is indicated or is found to be necessary or desirable.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.